Severe microcornea with anterior segment malformation in a mother and her son

A male infant with microcornea, anterior segment dysgenesis and congenital cataracts, but with a normal ocular posterior segment is reported. His mother also had extreme microcornea, no useful vision from birth, but had globes of grossly normal size.

Clinical features, treatment, and outcome in 108 patients with localized, high-grade synovial sarcoma (SS)

10584

Background: There remains ongoing controversy in the treatment of localized SS, with no clear consensus on routine use of chemotherapy. Methods: Between 1986 and 2007, 93 adult (AP) and 15 pediatric (PP) patients were diagnosed with high grade, localized SS at 2 centres in Toronto. Clinical records and pathology reports were examined. Survival distribution functions were estimated by Kaplan-meier and compared using Log-rank test. Results: Median age for AP and PP was 36 (range 14–76) and 14 (range 0.4–18) years, respectively. Sixty-six (61%) patients had large tumours (> 5 cm), 7 (6.5%) had neuro-vascular invasion, and 10 (9.3%) had bone invasion. 76 (82%) AP and 8 (53%) PP received radiation (RT). 16 (17%) AP and 13 (87%) PP received chemotherapy. All patients underwent definitive surgery with gross total resection; 9 patients (8 PP) had positive margins. Some patients received neoadjuvant chemotherapy, and response was evaluable in 15 patients: 10 SD, 2 PR, 1 CR, 1 PD. Relapse occurred in 32 patients: 28 distant, 3 local only, 1 local + distant. With a median follow-up of 5.6 years, EFS and OS was 72 ± 4.6% and 82 ± 4.2%, respectively and was similar for AP and PP. Patients with tumours > 5 cm had significantly worse EFS (63 ± 6.5%) compared to patients with small tumours (88 ± 5.4%, p=0.02), as did those with bone invasion (47 ± 18 vs.75 ± 4.9, p=0.05). The effect of chemotherapy was assessed in the entire cohort. Of 29 who received chemotherapy, 9 (31%) relapsed, and of 79 who did not receive chemotherapy, 23 (29%) relapsed. In patients with tumours >5 cm, relapse occurred in 41% (7/17) of those who received chemotherapy compared to 37% (18/49) in those that received no chemotherapy. Conclusions: Patients with SS < 5 cm have an excellent chance of cure with surgery and RT. Large tumours and those with evidence of bone invasion have a poor outlook. It is unlikely that chemotherapy contributes to an improvement in survival in SS.

No significant financial relationships to disclose.

Quality of life in advanced non-small cell lung cancer patients receiving first-line gefitinib monotherapy

9614

Background: Gefitinib is a potential first-line treatment option for patients with advanced non-small cell lung cancer (NSCLC), especially for patients with activating mutations in the EGFR gene. However, little is known about patient-reported health-related quality of life (HRQOL) in this patient population. The aims of this study were to explore the prognostic values of baseline HRQOL for time-to-treatment failure (TTF), as well as the predictors of repeatedly measured posttreatment HRQOL, in advanced NSCLC patients receiving first-line gefitinib. Methods: A total of 106 chemonaive patients with advanced NSCLC were enrolled in a phase II trial. Gefitinib was given at a dose of 250 mg/d. HRQOL was assessed monthly with the EuroQoL instrument (EQ-5D) and the Lung Cancer Symptom Scale (LCSS) questionnaire. Baseline HRQOL and clinical/molecular predictors of TTF were jointly examined by multiple Cox's proportional hazards model. The associations between the clinical/molecular factors and repeatedly measured posttreatment HRQOL were analyzed by fitting marginal linear regression model using the generalized estimating equations (GEE) method. Results: In this prospective study, HRQOL data were obtained from 94 patients. Baseline EQ-5D index (estimated hazard ratio = 0.286, 95% C.I.: 0.135–0.603, p = 0.001) and the presence of L858R EGFR mutation in adenocarcinoma (estimated hazard ratio = 0.520, 95% C.I.: 0.307–0.880, p = 0.015) were retained as independent prognostic factors in the final multiple Cox's proportional hazards model for TTF. According to preliminary GEE analysis of repeatedly measured posttreatment HRQOL, the patients with wild-type EGFR consistently had worse HRQOL in EQ-5D index (p < 0.0001), EQ-5D VAS score (p = 0.0002), and LCSS global score (p < 0.0001), respectively. Conclusions: In advanced NSCLC patients receiving first-line gefitinib, better baseline EQ-5D index and L858R EGFR mutation in adenocarcinoma predict longer TTF. In addition, patients with wild-type EGFR had worse posttreatment HRQOL.

No significant financial relationships to disclose.

Nomogram for predicting 5-year survival after primary surgery for epithelial ovarian cancer

5523

Background: Nomograms have been shown to be superior to traditional staging systems for predicting an individual's probability of long-term survival. Our objective was to develop a nomogram based on established prognostic factors to predict the probability of 5-year disease-specific survival (DSS) after primary surgery for patients with epithelial ovarian cancer (EOC) and to compare its predictive accuracy with the currently used FIGO staging system. Methods: We identified all pts with EOC who had their primary staging/cytoreductive surgery at our institution from January 1996-December 2004. DSS was estimated using the Kaplan-Meier method. We analyzed 28 clinical and pathologic factors for prognostic significance. Significant factors on univariate analysis were then included in the Cox proportional hazards regression model, which identified the factors to be used to construct the nomogram. The concordance index (CI) was used as an accuracy measure, with bootstrapping to correct for optimistic bias. Calibration plots were constructed. Results: There were 478 evaluable pts on the study. The median age was 58 years (range 25–96). The primary surgeon in all cases was an attending gynecologic oncologist. All patients received platinum-based systemic chemotherapy postop. DSS at 5 years was 52%. The most predictive nomogram was constructed using the following 7 predictor variables: age, ASA status, family history suggestive of hereditary breast/ovarian cancer syndrome, preoperative serum albumin level, FIGO stage, tumor histology, and residual disease status after primary surgery. This nomogram was internally validated using bootstrapping and shown to have excellent calibration with a bootstrap-corrected CI of 0.721. The CI for FIGO staging alone was significantly less at 0.62 (p = 0.002). Conclusions: We developed a nomogram to predict 5-year DSS after primary surgery for EOC. The nomogram uses 7 variables that are readily accessible, assigns a point value to each variable, and then predicts the probability of 5-year survival based on the total point value for an individual patient. This tool is more accurate than FIGO staging and should be useful for patient counseling, clinical trial eligibility determination, postop management, and follow-up.

No significant financial relationships to disclose.

Improvement of monocyte function and immune homeostasis by high volume continuous venovenous hemofiltration in patients with severe acute pancreatitis

BACKGROUND

Continuous renal replacement therapy (CRRT) showed promising results in the management of critically ill patients with systemic inflammatory response syndrome (SIRS)/sepsis. However, the underlying mechanism is still not very clear. A change of immune homeostasis in critically ill patients during CRRT was observed only to a smaller degree.

OBJECTIVE

The purpose of this study was to test the hypothesis that high-volume continuous venovenous hemofiltration (HV-CVVH) treatment could improve monocyte function and restore immune homeostasis in patients with severe acute pancreatitis (SAP).

METHODS

This was a prospective clinical trial in the surgical intensive care unit of a teaching hospital. Subjects were 16 patients with severe acute pancreatitis: sepsis group (n=7): positive culture result and in the late phase of disease (from onset of SAP to receiving CVVH therapy: more than 3 days); and nonseptic group (n=9): negative culture result and early phase of disease (less than 3 days). Patients received 72 hours of HV-CVVH. We measured the change in mean arterial pressure, APACHE II score, monocyte functions (including antigen-presenting and cytokine production ability), and plasma cytokines.

RESULTS

Mean arterial pressure were stable accompanied with APACHE II score improvements. HLA-DR expression on monocytes (antigen-presenting ability) were markedly decreased (p<0.0001) in all patients. Lipopolysaccharide (LPS)-induced TNF-alpha, interleukin-6 (IL-6), and IL-10 production from patients' monocytes markedly decreased in septic patients, but significantly increased in nonseptic patients. During HV-CVVH treatment, HLA-DR expression was markedly increased in nonseptic patients in 24 hours (p<0.05), and in septic patients in 72 hours (p<0.05). LPS-induced cytokine production was decreased in nonseptic patients, but not significantly changed in septic patients. The change of plasma cytokines showed the same trend.

CONCLUSIONS

In patients with SAP, HV-CVVH was associated with improved hemodynamics. HV-CVVH restores monocytes functions, especially in patients in the early phase of the disease and without sepsis. These findings suggest a potential role for HV-CVVH in the treatment of SAP.

Decision-aided maximum likelihood detection in coherent optical phase-shift-keying system

A novel decision-aided maximum likelihood (DA ML) technique is proposed to estimate the carrier phase in coherent optical phase-shift-keying system. The DA ML scheme is a totally linear computational algorithm which is feasible for on-line processing in the real systems. The simulation results show that the DA ML receiver can outperform the conventional Mth power scheme, especially when the nonlinear phase noise is dominant.

Comparative analysis of the post-lumpectomy target volume versus the use of pre-lumpectomy tumor volume for early stage breast cancer: implications for the future

Abstract #5134

Purpose: Accelerated partial breast irradiation (APBI) is increasingly being utilized for the treatment of early stage breast cancer. Planning target volume (PTV) generation with this approach is based on the post-lumpectomy cavity volume (post-LPC) and is often associated with treatment of large amounts of normal breast tissue which can result in patient ineligibility for external beam APBI (EB-APBI). In malignancies such as soft tissue sarcomas, neoadjuvant radiation therapy (RT) has been shown to be associated with smaller volumes of tissue irradiated compared to adjuvant RT. However, neoadjuvant RT has not been attempted in the setting of APBI. We hypothesized that a PTV generation based on an expansion of the pre-lumpectomy (pre-LP) intact tumor volume would result in a significant reduction in the volume of irradiated normal breast tissue compared to the current approach of using the post-LPC. We further hypothesize that the use of EB-APBI utilizing the pre-LP tumor will result in greater patient eligibility for APBI.&#x2028; Materials and Methods: 40 patients with 41 early stage breast cancers previously treated with breast conserving lumpectomy and RT were analyzed. Pre-operative imaging and pathology reports were used to determine a pre-LP tumor volume. A sphere, the diameter of which was the largest determined radiographic dimension, representing the pre-LP tumor volume was placed in the center of the previously contoured and treated lumpectomy cavity. PTVs were developed for the pre-LP tumor volume and the post-LPC volume as per the NSABP-B39 protocol guidelines. The pre-LP and post-LPC PTV volumes were compared. Suitability for APBI was analyzed using criteria set forth by NSABP-B39 guidelines.&#x2028; Results: For all patients, the pre-LP PTV was smaller than the post-LPC PTV. The median volume for the pre and post-LPC PTVs were 93 cc (range 24 – 570 cc) and 250 cc (range 45 – 879 cc), respectively. Paired t-test analysis demonstrated the pre-LP PTV to be significantly smaller than the post-LPC PTV, p &lt; 0.001. The average difference between pre-LP and post-LPC PTVs represented 173 cc (range 21 – 482 cc) or 18% (range 3 - 42%) of the whole breast volume. Based on our analysis, only 3 of 41 cases were ineligible for EB-APBI when using the pre-LP tumor volume, (2 based on pathologic criteria and 1 based on dose/volume constraints) while 13 of 41 cases were ineligible when using the post-LPC PTV (2 based on pathologic criteria and 11 based on dose/volume constraints).&#x2028; Conclusion: PTVs based on the pre-LP tumor expansion are likely to be associated with a significantly reduced amount of normal breast tissue irradiated compared to post-LPC PTVs potentially leading to improved breast cosmesis, decreased dose to critical structures and decreased toxicities. Additionally, eligibility for EB-APBI would potentially increase if administered in the pre-lumpectomy setting. The findings from this study support future investigation as to the implications and feasibility of neoadjuvant APBI.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5134.

Phase II trial of neoadjuvant chemotherapy of sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): a multi-centre study from British Columbia

Abstract #5118

Background: The role of trastuzumab either concurrent or sequential with adjuvant chemotherapy have clearly demonstrated significant benefits in early stage HER-2 positive breast cancer. There is now an accumulation of phase II and III trials also demonstrating improved pathological complete responses (pCR) in HER-2 positive breast cancer with neoadjuvant trastuzumab concurrent with chemotherapy. The number of patients on these trials are significantly fewer, and many of these trials are a mixture of primary operable and LABC. We have completed a multi-centre phase II trial of neoadjuvant chemotherapy and trastuzumab in HER-2 positive LABC.&#x2028; Methods: Women with HER-2 positive (IHC 3+ or FISH+) stage IIB-IIIC breast cancer were enrolled. Treatment consisted of 4 cycles of FEC100 (5-FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 4 cycles of TCH (Docetaxel 75 mg/m2, carboplatin AUC 6, trastuzumab 8 mg/kg loading then 6 mg/kg q3 weekly). Trastuzumab was also continued adjuvantly for 9 months following chemotherapy and surgery. Cardiac monitoring every 3 months was mandated. A correlative translational component with baseline and interval biopsies and serum collection was also performed.&#x2028; Results: A total of 30 patients (3 stage IIB; 14 IIIA; 10 IIIB and 3 IIIC) over a 3 year time period in 4 centres were accrued. Median age was 49 years (26-77 years). 60% of tumours were ER negative. There was one clinical CHF and 2 asymptomatic falls in LVEF requiring early discontinuation of trastuzumab. There were 3 episodes (10%) of febrile neutropenia. Seven patients underwent adjuvant radiotherapy prior to surgery. The pCR rate (breast and axilla) for the entire study population was 60% (18/30). There have been 3 recurrences so far (all biopsy proven) – of which 2 were brain metastases only. Further details on toxicity and changes in LVEF will be presented.&#x2028; Conclusions: This multi-centre phase II trial clearly demonstrates significant activity (pCR 60%) for neoadjuvant anthracyclines followed by concurrent taxane, platinum and trastuzumab in a HER-2 positive LABC population. Overall the treatment regimen was well tolerated. Brain metastases however appear to be a common site of relapse in this high risk patient population and further treatment strategies directed at this site should be investigated.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5118.

[Salivary stones and stenosis. A comprehensive classification]

INTRODUCTION

Sialendoscopy and sialo-MRI enable diagnosis of salivary gland obstructive pathologies, such as lithiasis, stenosis and dilatations. Therefore, a classification of these pathologies is needed, allowing large series comparisons, for better diagnosis and treatment of salivary pathologies.

MATERIAL AND METHODS

With help from people from the European Sialendoscopy Training Center (ESTC), the results of sialographies, sialoMRI and sialendoscopies, a comprehensive classification of obstructive salivary pathologies is described, based on the absence or presence of lithiasis (L), stenosis (S) and dilatation (D) ("LSD" classification).

DISCUSSION

It appears that a classification of salivary gland obstructive pathologies should be described. We hope it will be widely used and of course criticized to be improved and to compare the results of salivary gland diagnostic methods, such as sialography and sialendoscopy and also the results and indications for salivary gland therapeutic methods, such as lithotripsy, sialendoscopy and/or open surgery.

RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells

Gemcitabine is the first-line chemotherapeutic agent for advanced adenocarcinoma of the pancreas; however, chemoresistance to gemcitabine remains a major cause of failure for the clinical treatment of this disease. Polo-like kinase 1 (Plk-1) is highly expressed in pancreatic cancer cell lines and pancreatic tumour tissues, and is involved in a wide variety of cell cycle processes. Nevertheless, its biological role and implication for gemcitabine resistance are not clearly defined. In this study, we used RNA-interference (RNAi)-mediated depletion of Plk-1 to determine its potential for sensitizing pancreatic tumour cells to gemcitabine. We showed that the level of Plk-1 protein was correlated significantly with gemcitabine resistance in human pancreatic adenocarcinoma cells and that overexpression of Plk-1 reduced sensitivity to gemcitabine in these cells. In addition, small interfering RNA (siRNA)-mediated knockdown of Plk-1 caused cell cycle arrest at G2/M and the reduction of cellular proliferation. More importantly, the treatment of pancreatic cancer cells with Plk-1 siRNA followed by exposure to gemcitabine dramatically decreased cell viability and increased cellular apoptosis, as compared with treatment with either agent alone. These observations indicate that down-regulation of Plk-1 expression by RNAi enhances gemcitabine sensitivity and increases gemcitabine cytotoxicity in pancreatic tumour cells. This is the first demonstration that the combination of Plk-1 gene therapy and gemcitabine chemotherapy has synergistic anti-tumour activity against pancreatic carcinoma in vitro. This combination treatment warrants further investigation as an effective therapeutic regimen for patients with resistant pancreatic cancer and other tumours.

Inter-comparison of models to estimate radionuclide activity concentrations in non-human biota

A number of models have recently been, or are currently being, developed to enable the assessment of radiation doses from ionising radiation to non-human species. A key component of these models is the ability to predict whole-organism activity concentrations in a wide range of wildlife. In this paper, we compare the whole-organism activity concentrations predicted by eight models participating within the IAEA Environmental Modelling for Radiation Safety programme for a range of radionuclides to terrestrial and freshwater organisms. In many instances, there was considerable variation, ranging over orders of magnitude, between the predictions of the different models. Reasons for this variability (including methodology, data source and data availability) are identified and discussed. The active participation of groups responsible for the development of key models within this exercise is a useful step forward in providing the transparency in methodology and data provenance required for models which are either currently being used for regulatory purposes or which may be used in the future. The work reported in this paper, and supported by other findings, demonstrates that the largest contribution to variability between model predictions is the parameterisation of their transfer components. There is a clear need to focus efforts and provide authoritative compilations of those data which are available.

Dynamic gadolinium-enhanced MRI in early ischaemia of the proximal femoral epiphysis--a preliminary study

AIM

To compare the sensitivities of dynamic Gadoteridol (Gd)-enhanced magnetic resonance imaging (MRI) and conventional Gd-enhanced spin-echo (SE) T1-weighted imaging (WI) in the detection of decreased perfusion of early epiphyseal ischaemia, and to determine the contribution of metaphyseal vascularity to physeal perfusion in epiphyseal vascular occlusion by dynamic Gd-enhanced MRI.

MATERIALS AND METHODS

Twenty-eight 2-week-old piglets were divided evenly into four groups: control groups A and B, and ischaemic groups A and B (seven animals in each). In the ischaemic groups, MRI was performed bilaterally on hips in persistent hyperabduction for 30 min. In the control and ischaemic group A the piglets underwent dynamic Gd-enhanced MRI, and in control and ischaemic group B the piglets were subjected to Gd-enhanced SE T1WI.

RESULTS

In ischaemic group A, the enhancement ratio (ER) and enhancement speed (ES) of the various tissues (except the metaphysis) were significantly lower than those in control group A on dynamic Gd-enhanced MRI (p<0.05). However, in ischaemic group B, no significant decrease in the ER of each tissue was found, compared with the ER in control group B as viewed using Gd-enhanced SE T1WI (p>0.05). On dynamic Gd-enhanced MRI, the ER and ES of the physis were less than those of metaphysis in the ischaemic group A (p<0.05); however, the ER and ES of the physis were similar to those of metaphysis in control group A (p>0.05).

CONCLUSION

Dynamic Gd-enhanced MRI is more sensitive than conventional Gd-enhanced SE T1WI in the detection of early epiphyseal ischaemia. Physeal perfusion might be from the metaphysis in epiphyseal vascular occlusion.

Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia

OBJECTIVE

To evaluate the performance of screening for pre-eclampsia by uterine artery pulsatility index (PI) at 11 + 0 to 13 + 6 weeks' gestation and the change in uterine artery PI between 11 + 0 to 13 + 6 and 21 + 0 to 24 + 6 weeks.

METHODS

In 3107 singleton pregnancies attending for routine care at 11 + 0 to 13 + 6 and 21 + 0 to 24 + 6 weeks' gestation we recorded maternal characteristics and medical and obstetric history, and measured uterine artery PI. The distributions of uterine artery PI were made Gaussian after logarithmic transformation and the log of the ratio of uterine artery PI at 21 + 0 to 24 + 6 weeks to that at 11 + 0 to 13 + 6 weeks was calculated. Multiple regression analysis was used to determine which of the maternal variables and Doppler findings were significant predictors of early and late pre-eclampsia. The performance of screening was described by receiver-operating characteristics curves.

RESULTS

Pre-eclampsia developed in 93 (3.0%) pregnancies, including 22 (0.7%) in which delivery was before 34 weeks (early pre-eclampsia) and 71 (2.3%) with delivery at 34 weeks or more (late pre-eclampsia). Seventy-three (2.3%) women developed gestational hypertension, 346 (11.1%) delivered small-for-gestational-age (SGA) babies with no hypertensive disorders and 2595 (83.5%) were unaffected by pre-eclampsia, gestational hypertension or SGA. Multiple regression analysis demonstrated that maternal variables, uterine artery PI at 11 + 0 to 13 + 6 weeks and the change in uterine artery PI between 11 + 0 to 13 + 6 and 21 + 0 to 24 + 6 weeks' gestation provided significant independent contributions to the prediction of pre-eclampsia. For a false positive rate of 5% the predicted detection rates of early and late pre-eclampsia were 90.9 and 31.0%, respectively. The same performance of screening was achieved by reserving second-trimester testing for only the 20% of women at the highest risk after first-trimester screening.

CONCLUSION

The decrease in uterine artery PI between 11 + 0 to 13 + 6 and 21 + 0 to 24 + 6 weeks is steeper in pregnancies with a normal outcome than in those developing pre-eclampsia. Effective screening for pre-eclampsia can be achieved by the Doppler measurement of uterine artery PI at 11 + 0 to 13 + 6 weeks and the change in PI between 11 + 0 to 13 + 6 and 21 + 0 to 24 + 6 weeks.